Harmony Biosciences to Present at the Oppenheimer Rare and Orphan Disease Summit

Rhea-AI Summary

Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. President and CEO John C. Jacobs and Chief Medical Officer Dr. Jeffrey Dayno will host investor meetings during the event. The presentation will be accessible via a webcast on Harmony's investor page. The company focuses on developing therapies for rare neurological disorders with unmet medical needs.

News Market Reaction – HRMY

+0.40%

+0.40% Session move

In the trading session that priced this news, HRMY gained 0.40%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., May 18, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced that Harmony's President and CEO, John C. Jacobs and Chief Medical Officer, Dr. Jeffrey Dayno will present a company update and host investor meetings at the Oppenheimer Rare and Orphan Disease Summit on Friday, May 21, 2021.

A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/. 

About Harmony Biosciences 
Harmony Biosciences is a pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, with a vision to provide novel treatment options for people living with rare neurological disorders who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Investor Contact: 

Lisa Caperelli 
484-539-9736 
lcaperelli@harmonybiosciences.com 

Harmony Biosciences Media Contact: 

Nancy Leone 
215-891-6046 
nleone@harmonybiosciences.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/harmony-biosciences-to-present-at-the-oppenheimer-rare-and-orphan-disease-summit-301293012.html

SOURCE Harmony Biosciences

FAQ

What is Harmony Biosciences presenting at the Oppenheimer Rare and Orphan Disease Summit?

Harmony Biosciences will present a company update on May 21, 2021.

Who is presenting for Harmony Biosciences at the summit?

John C. Jacobs, President and CEO, and Dr. Jeffrey Dayno, Chief Medical Officer, will present.

Where can I access the webcast of Harmony Biosciences' presentation?

The webcast will be available on Harmony's investor page at their website.

When is the Oppenheimer Rare and Orphan Disease Summit?

The summit is scheduled for May 21, 2021.

What is the focus of Harmony Biosciences?

Harmony Biosciences focuses on developing therapies for rare neurological disorders with unmet medical needs.